Cosentyx Evrópusambandið - íslenska - EMA (European Medicines Agency)

cosentyx

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - Ónæmisbælandi lyf - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, einn eða ásamt stendur (metÓtrexati), er ætlað fyrir meðferð virk psoriasis liðagigt í fullorðinn sjúklinga þegar svar til fyrri sjúkdómur breyta gegn gigt eiturlyf (dmard) meðferð hefur verið ófullnægjandi. axial spondyloarthritis (axspa)hryggikt (eins og, röntgen axial spondyloarthritis)cosentyx er ætlað fyrir meðferð virk hryggikt í fullorðnir sem hafa brugðist ekki nægilega til að hefðbundin meðferð. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Dafiro Evrópusambandið - íslenska - EMA (European Medicines Agency)

dafiro

novartis europharm limited - meðferð, valsartan - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - meðferð við nauðsynlegum háþrýstingi. dafiro er ætlað sjúklingum sem blóðþrýstingur er ekki nægilega stjórn á meðferð eða valsartan sér.

DuoTrav Evrópusambandið - íslenska - EMA (European Medicines Agency)

duotrav

novartis europharm limited - hins vegar, notkunar í augu. - glaucoma, open-angle; ocular hypertension - augnlækningar - lækkun auga þrýstingur (iop) í fullorðinn sjúklinga með opnum-horn gláku eða auga háþrýstingur sem eru nægilega móttækilegur að baugi beta-blokkum eða prostaglandín hliðstæðum.

Entresto Evrópusambandið - íslenska - EMA (European Medicines Agency)

entresto

novartis europharm limited - sacubitril, valsartan - hjartabilun - ace ii hemla, önnur sturtu, umboðsmenn starfa á renín-ace kerfi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Enurev Breezhaler Evrópusambandið - íslenska - EMA (European Medicines Agency)

enurev breezhaler

novartis europharm ltd - Þannig brómíð - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - hver skammtur er ætlað sem viðhald berkjuvíkkandi meðferð til að létta einkenni í fullorðinn sjúklinga með langvinn veikindi í lungum (llt).

Eucreas Evrópusambandið - íslenska - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Exforge Evrópusambandið - íslenska - EMA (European Medicines Agency)

exforge

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - meðferð við nauðsynlegum háþrýstingi. exforge er ætlað sjúklingum sem blóðþrýstingur er ekki nægilega stjórn á meðferð eða valsartan sér.

Galvus Evrópusambandið - íslenska - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Hirobriz Breezhaler Evrópusambandið - íslenska - EMA (European Medicines Agency)

hirobriz breezhaler

novartis europharm limited - indacaterol maleat - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - hirobriz breezhaler er ætlað til meðhöndlunar berkjuvíkkandi meðferð á loftflæði hindrun hjá fullorðnum sjúklingum með langvinna lungnateppu.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Evrópusambandið - íslenska - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).